Need for extra treatment · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in need for additional treatment (up to 30 or 60 days) compared with acetylsalicylic acid (ASA) (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) · people undergoing initial treatment for KD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with different infusion regimens of IVIG (moderate certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation ( compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid probably leads to higher ulcer healing compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid probably leads to higher complete relief of rest pain compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with aspirin treatment (moderate certainty).
1 finding from 1 review
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in ulcer healing compared with placebo (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in complete relief of rest pain compared with placebo (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with placebo (moderate certainty).
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 30 days' limb ischaemiaa
It is very uncertain whether intra‐arterial delivery changes 30‐Day amputation‐free survival compared with intravenous delivery (very low certainty).
1 finding from 1 review
Amputation · patients with < 30 days' limb ischaemiaa
1 finding from 1 review
30‐Day mortality · patients with < 30 days' limb ischaemiaa
1 finding from 1 review